411 related articles for article (PubMed ID: 26510727)
1. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
Green CA; Scarselli E; Voysey M; Capone S; Vitelli A; Nicosia A; Cortese R; Thompson AJ; Sande CS; de Lara C; Klenerman P; Pollard AJ
BMJ Open; 2015 Oct; 5(10):e008748. PubMed ID: 26510727
[TBL] [Abstract][Full Text] [Related]
2. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
[TBL] [Abstract][Full Text] [Related]
3. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
Green CA; Scarselli E; Sande CJ; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Del Sorbo M; Angus B; Siani L; Di Marco S; Traboni C; Folgori A; Colloca S; Capone S; Vitelli A; Cortese R; Klenerman P; Nicosia A; Pollard AJ
Sci Transl Med; 2015 Aug; 7(300):300ra126. PubMed ID: 26268313
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.
Samy N; Reichhardt D; Schmidt D; Chen LM; Silbernagl G; Vidojkovic S; Meyer TP; Jordan E; Adams T; Weidenthaler H; Stroukova D; De Carli S; Chaplin P
Vaccine; 2020 Mar; 38(11):2608-2619. PubMed ID: 32057576
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.
Taylor G; Thom M; Capone S; Pierantoni A; Guzman E; Herbert R; Scarselli E; Napolitano F; Giuliani A; Folgori A; Colloca S; Cortese R; Nicosia A; Vitelli A
Sci Transl Med; 2015 Aug; 7(300):300ra127. PubMed ID: 26268314
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
Ruckwardt TJ; Morabito KM; Phung E; Crank MC; Costner PJ; Holman LA; Chang LA; Hickman SP; Berkowitz NM; Gordon IJ; Yamshchikov GV; Gaudinski MR; Lin B; Bailer R; Chen M; Ortega-Villa AM; Nguyen T; Kumar A; Schwartz RM; Kueltzo LA; Stein JA; Carlton K; Gall JG; Nason MC; Mascola JR; Chen G; Graham BS;
Lancet Respir Med; 2021 Oct; 9(10):1111-1120. PubMed ID: 33864736
[TBL] [Abstract][Full Text] [Related]
9. Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.
Jordan E; Kabir G; Schultz S; Silbernagl G; Schmidt D; Jenkins VA; Weidenthaler H; Stroukova D; Martin BK; De Moerlooze L
J Infect Dis; 2023 Oct; 228(8):999-1011. PubMed ID: 37079393
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.
de Waal L; Wyatt LS; Yüksel S; van Amerongen G; Moss B; Niesters HG; Osterhaus AD; de Swart RL
Vaccine; 2004 Feb; 22(8):923-6. PubMed ID: 15161069
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
13. Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.
Pierantoni A; Esposito ML; Ammendola V; Napolitano F; Grazioli F; Abbate A; Del Sorbo M; Siani L; D'Alise AM; Taglioni A; Perretta G; Siccardi A; Soprana E; Panigada M; Thom M; Scarselli E; Folgori A; Colloca S; Taylor G; Cortese R; Nicosia A; Capone S; Vitelli A
Mol Ther Methods Clin Dev; 2015; 2():15018. PubMed ID: 26015988
[TBL] [Abstract][Full Text] [Related]
14. Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
Jordan E; Lawrence SJ; Meyer TPH; Schmidt D; Schultz S; Mueller J; Stroukova D; Koenen B; Gruenert R; Silbernagl G; Vidojkovic S; Chen LM; Weidenthaler H; Samy N; Chaplin P
J Infect Dis; 2021 Mar; 223(6):1062-1072. PubMed ID: 32726422
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
[TBL] [Abstract][Full Text] [Related]
18. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
